Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Salzman

<< Previous

Bullboard Posts

Next >>

Comment by dayxdayon Apr 11, 2021 2:10pm

224 Views

Post# 32974583

RE:RE:RE:Salzman

Wayned52 wrote: Well I asked a pretty simple question , does Salzman own shares , and someone reposts a news release that doesn`t clear up anything . But he did gain a few thumbs up . Unbelievably the next guy reposts the post of the news release that the first guy posted . And judging by their reputations they are highly regarded on this board . Strange world .

Yes it is a pretty simple question. and you come here in stock house and ask it. do your due diligence and answer it yourself. don't come to a forum and ask them to do your due diligence for yourself. you cannot rely on info here, there are a lot of bashers and liars everywhere. do your own work it's your money DON'T be LAZY.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario